Trimetazidine therapy in hypertrophic cardiomyopathy
Research type
Research Study
Full title
A Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy.
IRAS ID
32371
Contact name
Perry Elliott
Contact email
Sponsor organisation
Joint UCLH/UCL/RFH Biomedical Research Unit
Eudract number
2011-000038-12
Clinicaltrials.gov Identifier
Research summary
Hypertrophic cardiomyopathy (HCM) is a common inherited heart condition that causes breathlessness, chest pain and fatigue. There are few treatments available. We have recently shown that a drug called perhexiline reduced symptoms and improved exercise capacity in patients with HCM. However, perhexiline is not widely available and the mechanism by which it works is not fully understood. The goal of this project is to test a similar drug, trimetazidine, in a group of symptomatic patients with HCM. The aims are to investigate its effects on symptoms, exercise capacity and heart function. We anticipate this may lead on to larger European clinical trial.
REC name
West of Scotland REC 1
REC reference
11/AL/0161
Date of REC Opinion
7 Jun 2011
REC opinion
Further Information Favourable Opinion